Free Trial

Capricor Therapeutics (CAPR) News Today

Capricor Therapeutics logo
$18.92 +0.46 (+2.49%)
(As of 11/20/2024 ET)
Capricor Therapeutics granted ODD, ATMP status for deramiocel by EMA
What is HC Wainwright's Forecast for CAPR FY2024 Earnings?
Capricor Therapeutics initiated with a Buy at JonesResearch
Capricor Therapeutics Inc stock logo
HC Wainwright Brokers Increase Earnings Estimates for CAPR
Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) - HC Wainwright increased their FY2024 EPS estimates for shares of Capricor Therapeutics in a report released on Thursday, November 14th. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company will post earnings per sh
Capricor Therapeutics Inc stock logo
Capricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Update
Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) was the recipient of a large drop in short interest in the month of October. As of October 31st, there was short interest totalling 5,280,000 shares, a drop of 14.6% from the October 15th total of 6,180,000 shares. Based on an average trading volume of 2,990,000 shares, the short-interest ratio is currently 1.8 days.
Q3 2024 Capricor Therapeutics Inc Earnings Call
Capricor Therapeutics Advances with Strategic Expansions
Capricor Therapeutics Inc stock logo
Capricor Therapeutics (NASDAQ:CAPR) Trading 7.3% Higher After Analyst Upgrade
Capricor Therapeutics (NASDAQ:CAPR) Stock Price Up 7.3% After Analyst Upgrade
Capricor Therapeutics Inc stock logo
Cantor Fitzgerald Boosts Capricor Therapeutics (NASDAQ:CAPR) Price Target to $30.00
Cantor Fitzgerald lifted their price objective on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the stock an "overweight" rating in a research report on Thursday.
Oppenheimer Sticks to Their Buy Rating for SAB Biotherapeutics (SABS)
Oppenheimer Keeps Their Buy Rating on Catalyst Pharma (CPRX)
Capricor Therapeutics Inc stock logo
Capricor Therapeutics (NASDAQ:CAPR) Stock Price Up 10.6% - What's Next?
Capricor Therapeutics (NASDAQ:CAPR) Shares Up 10.6% - Still a Buy?
Capricor Therapeutics Inc stock logo
Capricor Therapeutics (CAPR) Scheduled to Post Earnings on Wednesday
Capricor Therapeutics (NASDAQ:CAPR) will be releasing earnings after the market closes on Wednesday, November 13, Zacks reports.
Capricor Therapeutics Inc stock logo
Capricor Therapeutics (NASDAQ:CAPR) Stock Price Crosses Above Fifty Day Moving Average - What's Next?
Capricor Therapeutics (NASDAQ:CAPR) Shares Cross Above 50-Day Moving Average - Time to Sell?
Capricor Therapeutics Inc stock logo
Capricor Therapeutics Inc (NASDAQ:CAPR) Receives Average Recommendation of "Buy" from Brokerages
Shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) have received an average rating of "Buy" from the six brokerages that are covering the stock, Marketbeat reports. Six research analysts have rated the stock with a buy rating. The average 12-month price objective among analysts th
Alnylam Pharma (ALNY) Receives a Hold from Oppenheimer
Brainstorm Cell Therapeutics (BCLI) Receives a Buy from Maxim Group
Iterum Therapeutics (ITRM) Receives a Buy from Maxim Group
Capricor Therapeutics Inc stock logo
Capricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Up 17.9% in October
Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) was the recipient of a significant growth in short interest in the month of October. As of October 15th, there was short interest totalling 6,180,000 shares, a growth of 17.9% from the September 30th total of 5,240,000 shares. Based on an average daily volume of 2,880,000 shares, the days-to-cover ratio is currently 2.1 days.
Capricor Therapeutics Inc stock logo
Capricor Therapeutics (NASDAQ:CAPR) Trading Down 3.3% - Should You Sell?
Capricor Therapeutics (NASDAQ:CAPR) Trading Down 3.3% - Should You Sell?
Capricor Therapeutics initiated with an Overweight at Piper Sandler
Capricor Therapeutics Inc stock logo
Capricor Therapeutics (NASDAQ:CAPR) Trading Up 4.3% - Here's Why
Capricor Therapeutics (NASDAQ:CAPR) Shares Up 4.3% - What's Next?
Capricor Therapeutics Inc stock logo
Piper Sandler Begins Coverage on Capricor Therapeutics (NASDAQ:CAPR)
Piper Sandler began coverage on shares of Capricor Therapeutics in a research note on Monday. They issued an "overweight" rating and a $35.00 price target on the stock.
Capricor Therapeutics Inc
Capricor Therapeutics Inc stock logo
Capricor Therapeutics (NASDAQ:CAPR) Shares Gap Down - Time to Sell?
Capricor Therapeutics (NASDAQ:CAPR) Shares Gap Down - Time to Sell?
Get Capricor Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter.

JD Vance Predicts: Wall Street vs. Trump & Your Money (Ad)

Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.

Get your free guide NOW before it's too late.

CAPR Media Mentions By Week

CAPR Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CAPR
News Sentiment

0.46

0.46

Average
Medical
News Sentiment

CAPR News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CAPR Articles
This Week

24

4

CAPR Articles
Average Week

Get Capricor Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:CAPR) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners